What's breaking now, across thousands of outlets.
(MedPage Today) -- WASHINGTON -- At 6 months of age, most U.S. infants no longer had detectable levels of maternal neutralizing antibodies for measles, potentially leaving them at risk of an infection months before their first dose of the measles...
We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.
Early results of the first clinical trial to evaluate the drug invikafusp alfa (invika) in humans indicate that the treatment may be capable of managing cancers that have rebuffed most other…
The first Phase 3 data for a cancer vaccine has raised questions about whether the potential new treatment is needed.
The first Phase 3 data for a cancer vaccine has raised questions about whether the potential new treatment is needed.
Less than two years after a wave of administrative layoffs, Mass General Brigham began a new round of job cuts last week that affect clinical and operational programs, according to media reports.
The American Diabetes Association has issued two explanations, two reviews and an apology over its June convention. A Friday report adds new twists.
In data released at ESMO, the Moderna-Merck personalized mRNA cancer vaccine reduced recurrence-free survival and the time until distant metastasis occurred.
